Press Resease

Meningococcal Vaccines Market By Type (Combination Vaccines, Polysaccharide Vaccines, Conjugate Vaccines, and Men B Vaccines) and By End-User (Hospital Pharmacies, Retail Pharmacies, and Others): Global Industry Perspective, Comprehensive Analysis, and Forecast, 2018–2025

Published Date: 26-Sep-2019 Category: Healthcare Report Format : PDF Pages: 110 Report Code: ZMR-4775 Status : Published

Global meningococcal vaccines market expected to generate around USD 8,295 million by 2025, at a CAGR of around 11.73 % between 2019 and 2025. Meningococcal vaccine treats meningitidis that is caused by bacteria N. These vaccines are administered via injections.

Description

The report covers a forecast and an analysis of the meningococcal vaccines market on a global and regional level. The study provides historic data from 2016 to 2018 along with a forecast from 2019 to 2025 based revenue (USD Million). The study includes the drivers and restraints of the meningococcal vaccines market along with their impact on the demand over the forecast period. Additionally, the report includes the study of opportunities available in the meningococcal vaccines market on a global level.

In order to give the users of this report a comprehensive view of the meningococcal Vaccines Market, we have included a competitive landscape and an analysis of Porter’s Five Forces Model for the market. The study encompasses a market attractiveness analysis, where all the segments are benchmarked based on their market size, growth rate, and general attractiveness.

Global Meningococcal Vaccines Market

The report provides company market share analysis to give a broader overview of the key players in the market. In addition, the report also covers key strategic developments of the market including acquisitions & mergers, new technology launch, agreements, partnerships, collaborations & joint ventures, R&D, and regional expansion of major participants involved in the market on a global and regional basis. Moreover, the study covers price trend analysis and product portfolio of various companies according to regions.

The study provides a decisive view of the meningococcal vaccines market by segmenting it based on type, end-user, and region. All the segments have been analyzed based on present and future trends and the market is estimated from 2019 to 2025. The regional segmentation includes the current and forecast demand for North America, Europe, Asia Pacific, Latin America, and the Middle East and Africa.

Some key players of the meningococcal vaccines market are Novartis International, Nuron Biotech, GlaxoSmithKline, Pfizer, Sanofi, JN-International Medical, Baxter International, Serum Institute of India, and Biomed.

This report segments the global meningococcal vaccines market into:

Global Meningococcal Vaccines Market: Type Analysis

  • Combination Vaccines
    • Menhibrix
    • Menitorix
  • Polysaccharide Vaccines
    • Nmvac4
    • Menomune
    • Mencevax
    • Others
  • Conjugate Vaccines
    • Nimenrix
    • Menactra
    • Menveo
    • Menafrivac
    • Neisvac-C
    • Meningitec
    • Menjugate
    • Nmvac4-Dt
  • Men B Vaccines
    • Bexsero
    • Trumenba

Global Meningococcal Vaccines Market: End-User Analysis

  • Hospital Pharmacies
  • Retail Pharmacies
  • Others

Global Meningococcal Vaccines Market: Regional Analysis

  • North America
    • The U.S.
  • Europe
    • UK
    • France
    • Germany
  • Asia Pacific
    • China
    • Japan
    • India
  • Latin America
    • Brazil
  • Middle East and Africa

Table Of Content

  • Chapter 1. Introduction
    • 1.1. Report description and scope
    • 1.2. Research scope
    • 1.3. Research methodology
      • 1.3.1. Market research process
      • 1.3.2. Market research methodology
  •  
  • Chapter 2. Executive Summary
    • 2.1. Global Meningococcal Vaccines Market, 2016-2025 (USD Million)
    • 2.2. Global Meningococcal Vaccines Market: Snapshot
  •  
  • Chapter 3. Meningococcal Vaccines Market - Industry Dynamics
    • 3.1. Introduction
    • 3.2. Market drivers
      • 3.2.1. Rising healthcare expenditure
      • 3.2.2. Changing lifestyles of females globally
    • 3.3. Market restraints
      • 3.3.1. Harmful reactions of drugs
      • 3.3.2. High cost
    • 3.4. Opportunities
      • 3.4.1. Technological advancement
      • 3.4.2. Increase in R&D activities
    • 3.5. Porter's Five Forces Analysis
    • 3.6. Market attractiveness analysis
      • 3.6.1. Market attractiveness analysis, by Type
      • 3.6.2. Market attractiveness analysis, by End-User
      • 3.6.3. Market attractiveness analysis, by Region
  •  
  • Chapter 4. Global Meningococcal Vaccines Market - Competitive Landscape
    • 4.1. Company Market Share Analysis
      • 4.1.1. Global Meningococcal Vaccines Market: company market share, 2018
    • 4.2. Strategic Development
      • 4.2.1. Acquisitions & Mergers
      • 4.2.2. New Launch
      • 4.2.3. Agreements, Partnerships, Collaborations and Joint Ventures
      • 4.2.4. R&D
      • 4.2.5. Regional Expansion
    • 4.3. Price Trend Analysis
    • 4.4. Type Portfolio
    • 4.5. Global Meningococcal Vaccines Market - Type Analysis
    • 4.6. Global Meningococcal Vaccines Market: Type overview
      • 4.6.1. Global meningococcal vaccines market share, by Type, 2018 and 2025
    • 4.7. Combination Vaccines
      • 4.7.1. Global Combination Vaccines Market, 2016-2025 (USD Million)
    • 4.8. Polysaccharide Vaccines
      • 4.8.1. Global Polysaccharide Vaccines Market, 2016-2025 (USD Million)
    • 4.9. Conjugate Vaccines
      • 4.9.1. Global Conjugate Vaccines Market, 2016-2025 (USD Million)
    • 4.10. Men B Vaccines
      • 4.10.1. Global Men B Vaccines Market, 2016-2025 (USD Million)
  •  
  • Chapter 5. Global Meningococcal Vaccines Market - End-User Analysis
    • 5.1. Global Meningococcal Vaccines Market: End-User overview
      • 5.1.1. Global Meningococcal Vaccines Market share, by End-User, 2018 and 2025
    • 5.2. Hospital Pharmacies
      • 5.2.1. Global Hospital Pharmacies Market, 2016-2025 (USD Million)
    • 5.3. Retail Pharmacies
      • 5.3.1. Global Retail Pharmacies Market, 2016-2025 (USD Million)
    • 5.4. Others
      • 5.4.1. Global Others Market, 2016-2025 (USD Million)
  •  
  • Chapter 6. Global Meningococcal Vaccines Market - Regional Analysis
    • 6.1. Global Meningococcal Vaccines Market: Regional overview
      • 6.1.1. Global Meningococcal vaccines market share, by region, 2018 and 2025
    • 6.2. North America
      • 6.2.1. North America Meningococcal vaccines market revenue, by Type, 2016-2025 (USD Million)
      • 6.2.2. North America Meningococcal vaccines market revenue, by End-User, 2016-2025 (USD Million)
      • 6.2.3. The U.S.
        • 6.2.3.1. The U.S. Meningococcal vaccines market revenue, by Type, 2016-2025 (USD Million)
        • 6.2.3.2. The U.S. Meningococcal vaccines market revenue, by End-User, 2016-2025 (USD Million)
      • 6.2.4. Rest of North America
        • 6.2.4.1. Rest of North America Meningococcal vaccines market revenue, by Type, 2016-2025 (USD Million)
        • 6.2.4.2. Rest of North America Meningococcal vaccines market revenue, by End-User, 2016-2025 (USD Million)
    • 6.3. Europe
      • 6.3.1. Europe Meningococcal vaccines market revenue, by Type, 2016-2025 (USD Million)
      • 6.3.2. Europe Meningococcal vaccines market revenue, by End-User, 2016-2025 (USD Million)
      • 6.3.3. Germany
        • 6.3.3.1. Germany Meningococcal vaccines market revenue, by Type, 2016-2025 (USD Million)
        • 6.3.3.2. Germany Meningococcal vaccines market revenue, by End-User, 2016-2025 (USD Million)
      • 6.3.4. France
        • 6.3.4.1. France Meningococcal vaccines market revenue, by Type, 2016-2025 (USD Million)
        • 6.3.4.2. France Meningococcal vaccines market revenue, by End-User, 2016-2025 (USD Million)
      • 6.3.5. UK
        • 6.3.5.1. UK Meningococcal vaccines market revenue, by Type, 2016-2025 (USD Million)
        • 6.3.5.2. UK Meningococcal vaccines market revenue, by End-User, 2016-2025 (USD Million)
      • 6.3.6. Rest of Europe
        • 6.3.6.1. Rest of Europe Meningococcal vaccines market revenue, by Type, 2016-2025 (USD Million)
        • 6.3.6.2. Rest of Europe Meningococcal vaccines market revenue, by End-User, 2016-2025 (USD Million)
    • 6.4. Asia Pacific
      • 6.4.1. Asia Pacific Meningococcal vaccines market revenue, by Type, 2016-2025 (USD Million)
      • 6.4.2. Asia Pacific Meningococcal vaccines market revenue, by End-User, 2016-2025 (USD Million)
      • 6.4.3. China
        • 6.4.3.1. China Meningococcal vaccines market revenue, by Type, 2016-2025 (USD Million)
        • 6.4.3.2. China Meningococcal vaccines market revenue, by End-User, 2016-2025 (USD Million)
      • 6.4.4. Japan
        • 6.4.4.1. Japan Meningococcal vaccines market revenue, by Type, 2016-2025 (USD Million)
        • 6.4.4.2. Japan Meningococcal vaccines market revenue, by End-User, 2016-2025 (USD Million)
      • 6.4.5. India
        • 6.4.5.1. India Meningococcal vaccines market revenue, by Type, 2016-2025 (USD Million)
        • 6.4.5.2. India Meningococcal vaccines market revenue, by End-User, 2016-2025 (USD Million)
      • 6.4.6. Rest of Asia Pacific
        • 6.4.6.1. Rest of Asia Pacific Meningococcal vaccines market revenue, by Type, 2016-2025 (USD Million)
        • 6.4.6.2. Rest of Asia Pacific Meningococcal vaccines market revenue, by End-User, 2016-2025 (USD Million)
    • 6.5. Latin America
      • 6.5.1. Latin America Meningococcal vaccines market revenue, by Type, 2016-2025 (USD Million)
      • 6.5.2. Latin America Meningococcal vaccines market revenue, by End-User, 2016-2025 (USD Million)
      • 6.5.3. Brazil
        • 6.5.3.1. Brazil Meningococcal vaccines market revenue, by Type, 2016-2025 (USD Million)
        • 6.5.3.2. Brazil Meningococcal vaccines market revenue, by End-User, 2016-2025 (USD Million)
      • 6.5.4. Rest of Latin America
        • 6.5.4.1. Rest of Latin America Meningococcal vaccines market revenue, by Type, 2016-2025 (USD Million)
        • 6.5.4.2. Rest of Latin America Meningococcal vaccines market revenue, by End-User, 2016-2025 (USD Million)
    • 6.6. The Middle East and Africa
      • 6.6.1. The Middle East and Africa Meningococcal vaccines market revenue, by Type, 2016-2025 (USD Million)
      • 6.6.2. The Middle East and Africa Meningococcal vaccines market revenue, by End-User, 2016-2025 (USD Million)
  •  
  • Chapter 7. Company Profile
    • 7.1. Novartis International
      • 7.1.1. Overview
      • 7.1.2. Financials
      • 7.1.3. Type portfolio
      • 7.1.4. Business strategy
      • 7.1.5. Recent developments
    • 7.2. Nuron Biotech
      • 7.2.1. Overview
      • 7.2.2. Financials
      • 7.2.3. Product Type portfolio
      • 7.2.4. Business strategy
      • 7.2.5. Recent developments
    • 7.3. GlaxoSmithKline
      • 7.3.1. Overview
      • 7.3.2. Financials
      • 7.3.3. Product Type portfolio
      • 7.3.4. Business strategy
      • 7.3.5. Recent developments
    • 7.4. Pfizer
      • 7.4.1. Overview
      • 7.4.2. Financials
      • 7.4.3. Product Type portfolio
      • 7.4.4. Business strategy
      • 7.4.5. Recent developments
    • 7.5. Sanofi
      • 7.5.1. Overview
      • 7.5.2. Financials
      • 7.5.3. Product Type portfolio
      • 7.5.4. Business strategy
      • 7.5.5. Recent developments
    • 7.6. JN-International Medical
      • 7.6.1. Overview
      • 7.6.2. Financials
      • 7.6.3. Product Type portfolio
      • 7.6.4. Business strategy
      • 7.6.5. Recent developments
    • 7.7. Baxter International
      • 7.7.1. Overview
      • 7.7.2. Financials
      • 7.7.3. Product Type portfolio
      • 7.7.4. Business strategy
      • 7.7.5. Recent developments
    • 7.8. Serum Institute of India
      • 7.8.1. Overview
      • 7.8.2. Financials
      • 7.8.3. Product Type portfolio
      • 7.8.4. Business strategy
      • 7.8.5. Recent developments
    • 7.9. Biomed
      • 7.9.1. Overview
      • 7.9.2. Financials
      • 7.9.3. Product Type portfolio
      • 7.9.4. Business strategy
      • 7.9.5. Recent developments

Methodology

Free Analysis

Meningococcal vaccine treats meningitidis that is caused by bacteria N. These vaccines are administered via injections. In nations with low illness danger, they suggest immunizing high-risk groups. Generally, meningococcal vaccines are secure, but some individuals may feel pain and redness at the injection site. However, in less than one in a million doses, severe allergic responses are recorded.

Developing nations like Brazil, Russia, India, China, and South Africa are progressively engaged in improvising and expanding their health infrastructure along with investing heavily in innovation in health, progressively impacting the health procedures worldwide. Thus, to develop innovative health technologies, the Indian government is increasingly investing in the early phase of different research and development projects. Therefore, high-quality, low-cost vaccines produced by developing countries are likely to drive the meningococcal vaccines market. Furthermore, rising awareness about the meningococcal vaccines is also fuelling the meningococcal vaccines market development. Many leading companies are collaborating with non-profit organizations to create awareness about the disease and its various treatment options for meningococcal infections. Visits to healthcare facilities should be used to evaluate the status of immunization and administer suggested vaccines to allow maximum number of adolescents access to these vaccines. Alternative sites can also be used to maximize vaccination possibilities, such as colleges or pharmacies.

Global Meningococcal Vaccines Market

The meningococcal vaccines market is fragmented into type and end-user. Based on type, the market is classified into combination (MenHibrix and Menitorix), polysaccharide (NmVac4, Mencevax, Menomune, and others), conjugate (Menjugate, Nimenrix, Menveo, Menactra, NeisVac-C, MenAfriVac, Meningitec, and NmVac4-DT), and Men B vaccines (Bexsero and Trumenba). The end-user segment is classified into hospital pharmacies, retail pharmacies, and others.

North America is anticipated to lead the meningococcal vaccines market worldwide, owing to the increasing public measures and prevention programs and research and growth projects by multiple regional producers. Group-B vaccines have been custom-made for particular epidemic strains and are widely used in Cuba, Brazil, New Zealand, France, Chile, and Norway. In developed nations like Australia, Canada, and certain European countries, the incidence of meningococcal illnesses decreased before the advent of the vaccine, which further accelerated the disease's decline. This is followed by the regions of Latin America and the Middle East and Africa. Due to low production costs and increased healthcare expenditure, the Asia Pacific region is anticipated to be the fastest-growing in the meningococcal vaccines market.

Some key players of the meningococcal vaccines market are Novartis International, Nuron Biotech, GlaxoSmithKline, Pfizer, Sanofi, JN-International Medical, Baxter International, Serum Institute of India, and Biomed.

}
Office Address

Corporate Office
Zion Market Research 244 Fifth Avenue, Suite N202 New York, 10001, United States
Tel: +49-322 210 92714
USA/Canada Toll Free No.1-855-465-4651

Asia Pacific Office
3rd Floor, Mrunal Paradise, Opp Maharaja Hotel, Pimple Gurav, Pune 411061, Maharashtra, India
Phone No 020-46277770

Contact #
US OFFICE NO +1-386-310-3803
US/CAN TOLL FREE +1-855-465-4651
Email: sales@zionmarketresearch.com